⌘K

Login Start Free

Home/Filings/4/0001193125-25-237295

4//SEC Filing

Graham G. Walmsley 4

Accession 0001193125-25-237295

CIK 0001744659other

View on SEC.gov Company Profile

Filed

Oct 9, 8:00 PM ET

Accepted

Oct 10, 7:48 PM ET

Size

21.5 KB

Accession

0001193125-25-237295

Insider Transaction Report

Form 4

Period: 2025-10-08

Akero Therapeutics, Inc.AKRO

Graham G. Walmsley

Director

Transactions

Exercise/Conversion
Common Stock
2025-10-08$23.02/sh+26,000$598,520→ 28,168 total
Exercise/Conversion
Common Stock
2025-10-08$25.20/sh+13,000$327,600→ 69,168 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−26,000→ 0 total
Exercise: $23.02Exp: 2034-06-07→ Common Stock (26,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−13,000→ 0 total
Exercise: $26.32Exp: 2031-05-31→ Common Stock (13,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−23,832→ 0 total
Exercise: $19.97Exp: 2029-11-07→ Common Stock (23,832 underlying)
Exercise/Conversion
Common Stock
2025-10-08$8.13/sh+15,000$121,950→ 43,168 total
Exercise/Conversion
Common Stock
2025-10-08$26.32/sh+13,000$342,160→ 56,168 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−15,000→ 0 total
Exercise: $8.13Exp: 2032-06-01→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−13,000→ 0 total
Exercise: $25.20Exp: 2030-05-31→ Common Stock (13,000 underlying)
Exercise/Conversion
Common Stock
2025-10-08$19.97/sh+23,832$475,925→ 93,000 total

Holdings

Common Stock
(indirect: See Footnote)
1,200,000

Footnotes (2)

[F1]The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
[F2]The options are vested and currently exercisable.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Akero Therapeutics, Inc.

CIK 0001744659

Entity typeother

IncorporatedDE

Related Parties

1

filerCIK 0001777517

Filing Metadata

Form type: 4
Filed: Oct 9, 8:00 PM ET
Accepted: Oct 10, 7:48 PM ET
Size: 21.5 KB

View on SEC.gov